Amy H Huang

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8383060/publications.pdf

Version: 2024-02-01

25 papers	557 citations	687363 13 h-index	22 g-index
25	25	25	433
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Inpatient burden of hidradenitis suppurativa in the United States: analysis of the 2016 National Inpatient Sample. Journal of Dermatological Treatment, 2022, 33, 1150-1152.	2.2	2
2	Real-world disease burden and comorbidities of pediatric prurigo nodularis. Journal of the American Academy of Dermatology, 2022, 86, 655-657.	1.2	6
3	Real-world comorbidities of atopic dermatitis in the US adult ambulatory population. Journal of the American Academy of Dermatology, 2022, 86, 835-845.	1.2	21
4	Psoriasis and mortality in the United States: Data from the National Health and Nutrition Examination Survey. Journal of the American Academy of Dermatology, 2021, 85, 396-403.	1.2	39
5	Examining the landscape of skin of color dermatoses: A cross-sectional study at an urban tertiary care center. Journal of the American Academy of Dermatology, 2021, 85, 234-237.	1.2	1
6	Clinical characteristics and disease burden in prurigo nodularis. Clinical and Experimental Dermatology, 2021, 46, 1277-1284.	1.3	22
7	A Nationwide Study of Prurigo Nodularis: Disease Burden and Healthcare Utilization in the United States. Journal of Investigative Dermatology, 2021, 141, 2530-2533.e1.	0.7	17
8	Real-world comorbidities of atopic dermatitis in the pediatric ambulatory population in the United States. Journal of the American Academy of Dermatology, 2021, 85, 893-900.	1.2	33
9	Photoprotective Behaviors in Patients With Depressive Symptoms: Analysis of the 2015 National Health Interview Survey. Dermatologic Surgery, 2021, 47, 878-879.	0.8	O
10	Association of basophil parameters with disease severity and duration in chronic spontaneous urticaria (CSU). Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, 793-795.e6.	3.8	21
11	Real-World Prevalence of Prurigo Nodularis and Burden of Associated Diseases. Journal of Investigative Dermatology, 2020, 140, 480-483.e4.	0.7	75
12	Analysis of real-world treatment patterns in patients with prurigo nodularis. Journal of the American Academy of Dermatology, 2020, 82, 34-36.	1.2	23
13	Retrospective case series of increased oral propranolol dosage for infantile hemangiomas. Pediatric Dermatology, 2020, 37, 1057-1062.	0.9	5
14	Healthcare resource utilization and payer cost analysis of patients with prurigo nodularis. British Journal of Dermatology, 2020, 183, 182-184.	1.5	14
15	Photoaging: a Review of Current Literature. Current Dermatology Reports, 2020, 9, 22-29.	2.1	46
16	Prurigo nodularis. Journal of the American Academy of Dermatology, 2020, 83, 1567-1575.	1.2	85
17	Prurigo nodularis. Journal of the American Academy of Dermatology, 2020, 83, 1559-1565.	1.2	77
18	Association of particulate matter air pollution and itch: A digital epidemiology approach. Journal of the American Academy of Dermatology, 2019, 81, 1409-1410.	1.2	5

Amy H Huang

#	Article	IF	CITATION
19	Pruritus Associated with Commonly Prescribed Medications in a Tertiary Care Center. Medicines (Basel, Switzerland), 2019, 6, 84.	1.4	11
20	Periocular infantile hemangiomas: Characteristics, ocular sequelae, and outcomes. Pediatric Dermatology, 2019, 36, 830-834.	0.9	8
21	Baltimore Reading and Eye Disease Study (BREDS): compliance and satisfaction with glasses usage. Journal of AAPOS, 2019, 23, 207.e1-207.e6.	0.3	8
22	Association Between Psoriasis with Arthritis and Hearing Impairment in US Adults: Data from the National Health and Nutrition Examination Survey. Journal of Rheumatology, 2019, 46, 587-594.	2.0	4
23	Topical timolol as adjunct therapy to shorten oral propranolol therapy for infantile hemangiomas. Pediatric Dermatology, 2019, 36, 283-289.	0.9	15
24	Racial Disparities in the Clinical Presentation and Prognosis of Patients with Mycosis Fungoides. Journal of the National Medical Association, 2019, 111, 633-639.	0.8	17
25	Proteomic and Phosphoproteomic Analysis Reveals that Neurokinin-1 Receptor (NK1R) Blockade with Aprepitant in Human Keratinocytes Activates a Distinct Subdomain of EGFR Signaling: Implications for the Anti-Pruritic Activity of NK1R Antagonists. Medicines (Basel, Switzerland), 2019, 6, 114.	1.4	2